Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41−0.03 (-2.08%)
Close on Nov 17, 2026Market cap $6.31MP/E –Yield –
Enveric Biosciences revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Enveric Biosciences's revenue for the twelve months ending Sep 30, 2020 was $35.41M, down 13.9% year over year. For fiscal 2019 it was $39.91M, down 7.2% from the year before. The highest annual figure on record is $48.59M in fiscal 2017.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $39.91M | -7.2% |
| FY2018 | Dec 31, 2018 | $43.00M | -11.5% |
| FY2017 | Dec 31, 2017 | $48.59M | +34.4% |
| FY2016 | Dec 31, 2016 | $36.15M | +78.4% |
| FY2015 | Dec 31, 2015 | $20.26M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | $8.48M | -7.3% |
| Q2 FY2020 | Jun 30, 2020 | $8.25M | -25.1% |
| Q1 FY2020 | Mar 31, 2020 | $9.60M | -10.1% |
| Q4 FY2019 | Dec 31, 2019 | $9.06M | -11.9% |
| Q3 FY2019 | Sep 30, 2019 | $9.15M | -13.5% |
| Q2 FY2019 | Jun 30, 2019 | $11.02M | -0.5% |
| Q1 FY2019 | Mar 31, 2019 | $10.69M | -3.4% |
| Q4 FY2018 | Dec 31, 2018 | $10.28M | -10.2% |
| Q3 FY2018 | Sep 30, 2018 | $10.58M | -15.6% |
| Q2 FY2018 | Jun 30, 2018 | $11.08M | -9.7% |
| Q1 FY2018 | Mar 31, 2018 | $11.06M | -10.4% |
| Q4 FY2017 | Dec 31, 2017 | $11.45M | -7.5% |
| Q3 FY2017 | Sep 30, 2017 | $12.53M | +24.6% |
| Q2 FY2017 | Jun 30, 2017 | $12.27M | – |
| Q1 FY2017 | Mar 31, 2017 | $12.34M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.39M | – |
| Q3 FY2016 | Sep 30, 2016 | $10.06M | – |
See a number that looks wrong?